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Abstract
Apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) is
an important adaptor protein for inflammasome activation, mediating the secretion of protu-
morigenic innate cytokines. However, ASC is also known to trigger apoptosis in tumor cells,
acting as a tumor-suppressor gene, which is lost in several human cancers. The aim of this
study was to evaluate the clinical significance of ASC in human cutaneous squamous cell
carcinoma (SCC). Initially, ASC expression was immunohistochemically evaluated in non-
metastic and metastatic SCC. While ASC expression does not correlate with metastatic
potential, it correlates with the degree of dedifferentiation. Using methylation specific PCR
we were able to demonstrate ASC silencing by promotor specific methylation and impaired
inflammasome function in methylated cell lines, linking epigenetic modifications to innate
immune activation in keratinocytes. Interestingly, upon ASC restoration by treatment with
demethylating agents, we were able to restore AIM2 and NLRP3 activation. In summary,
loss of ASC driven tumor development is counterbalanced in the identical cell by the inhibi-
tion of pro-tumorigenic inflammation in the tumor cell itself.
Introduction
Non-melanoma skin cancer is the most common cancer in humans. While basal cell carcinoma
(BCC) does not have a precursor and rarely metastasizes, cutaneous squamous cell carcinoma
(SCC) is often preceded by an in-situ carcinoma and able to spread to regional lymph nodes
and in rare cases to other organs. Histologically, SCCs are graded via the grade of differentia-
tion [1]. The grade of differentiation and the horizontal size of the tumors were considered to
be the key determinants of patient outcome [2]. Recent data however determined vertical
tumor thickness as the most important prognostic marker for developing metastasis [3].
Besides UV exposure, human papilloma virus (HPV) or chronic inflammation as seen in
acne inversa, lichen planus or chronic wounds are known to be the main risk factors for
tumor-development [4]. In contrast, immunosuppressed patients have a higher incidence of
SCC and a higher risk of metastasis, pointing towards an ambiguous role of inflammation [5].
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Important cytokines of early innate immune responses in the skin are TNF and Interleukin
(IL)-1 family members [6][7].
The inflammasome adaptor ASC (Apoptosis-associated speck-like protein containing a
CARD, PYCARD) is essential for the secretion of IL-1β. IL-1β is cleaved by activated caspase-
1. This inflammatory, non-apoptotic caspase is proteolytically processed by cytosolicmultipro-
tein-complexes called inflammasomes.Myeloid cells deficient in ASC show an impaired secre-
tion of IL-1β [8] and for IL-1α [9] after NLRP3- or AIM2-inflammasomeactivation. However,
aside from its role in caspase-1 activation, ASC functions as a tumor suppressor gene. Down-
regulation of ASC expression by aberrant methylation was described in numerous cancers,
including melanoma and breast cancer.
Recent studies have provided evidence that inflammation can drive tumor development, but
the molecularmechanisms converting tissue inflammation into a tumor-growth remain largely
elusive. In a mouse-model of inflammation-inducedcutaneous SCC, we demonstrated that acti-
vated IL-1-signaling promotes cancer development [10]. IL-1 receptor- or caspase-1-deficient
mice showed reduced cancer incidence and tumor number compared to wild-type.However,
mice deficient for ASC were not protected against cancer development. To differentiate the puta-
tive tumor-suppressive role of ASC in the keratinocyte from its tumor-promoting functions as an
inflammasome adaptor, mice deficient for the inflammasome adaptor protein ASC exclusively in
myeloid cells (ASCf/f-LysM-Cre+) and mice specificallydeficient for ASC in keratinocytes (ASCf/
fK14-Cre+) were generated.While ASCf/fK14-Cre+mice developedmore tumors than controls,
ASCf/f-LysM-Cre+mice were protected against cancer, suggesting that in contrast to its pro-
inflammatory role in myeloid cells, ASC acts as a tumor-suppressor in skin epithelial cells [10].
In this study, we investigate human primary SCCs of various grades of differentiation,
tumor-thickness and outcome to determine whether ASC expression correlates with tumor
progression or metastasis of the tumor. Further, we aim to determine whether reversing meth-
ylation in SCC-tumorsmight reestablish the capacity of caspase-1 activation. The resulting
data might define promotor methylation as an important factor controlling immune activation
in cancer cells.
Materials and Methods
Patients
72 patients who underwent surgery and were clinically followed up at the Department of Der-
matology, University of Tuebingen, Germany, were eligible to be included in the study. Retro-
spectively, excisions with an identical tumor thickness, but different grades of differentiation in
histology were paired. Paraffin embedded formalin fixed tissue of patients with a known his-
tory of SCCmetastasis were drawn from the files of the Histopathology Unit of the Department
of Dermatology, University of Tuebingen, and were matched to an excision from a patient
without metastatic disease. As control groups we included biopsies of BCC and condylomata
acuminata which were also drawn from the archives of the Histopathology Unit of the Depart-
ment of Dermatology, University of Tuebingen. This study was approved by our local ethics
committee (317/2016BO2). According to the recommendations of our ethics committee,
patients whose biopsies were taken between 2012 and 2014 gave written consent. The mean
age at diagnosis was 78 years. The mean tumor thickness of the G1 and G3 tumors of SCC was
6.0 mm and 7.7 mm, respectively (Table 1).
Immunohistochemistry
4μm sections were cut from the paraffin blocks and treated with 10mM sodium citrate buffer
for antigen retrieval. ASC was stained with a rabbit anti-human ASC (Adipogene, Switzerland)
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antibody at a dilution of 1:1000. ASC immunoreactivity was classified into three grades as
describedpreviously:Less than 33% positivity of tumor cells (score 1); 34–66% positivity of
tumor cells (score 2); 67–100% positivity of tumor cells (score 3)[11].
Real-time PCR
Total RNA was extracted from primary human keratinocytes which were isolated as described
previously [9] or the various SCC cell lines using the RNeasay Kit (Qiagen). After on-column
DNA-digest according to the manufacturer´s instruction, RNA concentration was determined
using a Nano Drop spectrophotometer (Thermo Scientific). Superscript II Reverse transcrip-
tase (Life Technologies) was used for cDNA synthesis, ASC-expression quantified on a Light
Cycler 480 (Roche) instrument with a SYBR-green qPCRmaster mix (Roche).
Bisulfite conversion andMethylation-specificPCR. Genomic DNA was isolated using
the DNA Blood and Tissue kit (Qiagen) after proteinase K digestion. DNA yield was measured
with a Nano Drop spectrophotometer (Thermo Scientific). Prior to methylation-specific PCR,
DNA was bisulfite converted. Utilizing the EZ-DNA Methylation kit (Zymo) DNA was first
denatured to then desulphonate DNA for conversion of Cytosine into Uracil. After purifica-
tion, 2μg of bisulfite-treatedDNA was subjected to methylation specific PCR, using EpiMark
Taq Polymerase (Zymo) and primers matching targets of either the methylated or unmethy-
lated sequence of ASC [12]. Where indicated, cells were treated with 5-aza-2’-deoxycytidine at
a concentration of 2.5 μM or 5 μM for four days. Medium containing 5-aza-2’-deoxycytidine
was changed every day. The cells were lysed using a hypertonic lysis buffer and loaded on a gel
for Western blot. Secretion of IL-1α and IL-1β from SCC-cell lines was quantified using the
Ready-SET-Go ELISA kits (ebioscience) according to the manufacturer´s instructions. Statisti-
cal analysis was performed using an unpaired t-test.
Results
ASC expression correlates with differentiation, but not with metastasis
Immunohistochemically, ASC stains the normal epidermis in particular in suprabasal layers,
while the basal keratinocytes only show a weak-staining intensity (Fig 1). To evaluate whether
ASC-expressionmight be reduced in cutaneous SCC, SCC of identical tumor thickness, but dif-
ferent grading were stained for ASC. For grading, a modified protocol of Broders using a three
tier-grading system was applied. Well differentiated tumors carried<25% (Broders 1) dediffer-
entiated tumor cells, while poorly differentiated tumors contained> 50% dedifferentiated
tumor cells (Broders G3 and G4) [1].
We could observeASC staining in most of the well-differentiated tumors (Fig 1A). In partic-
ular areas with keratinization such as keratin pearls displayed strong immunoreactivity for the
Table 1. Metastatic and non-metastatic SCC and well (G1) and poorly (G3) differentiated SCC do not differ in age or tumor thickness.
Age (years) Invasion (mm) ASC 0–33% ASC 34–66% ASC 67–100%
All SCC 78 6,9 21 15 10
Metastasized 76 7,4 4 4 5
Non metastasized 78 6,8 17 11 5
G1 76 6 4 7 7
G3 79 7,7 17 8 3
ASC is more frequently expressed in well-differentiated SCC, but ASC stainig does not differ between metastatic and non-metastatic SCC.
doi:10.1371/journal.pone.0164742.t001
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staining (Fig 1A). In contrast, areas of dedifferentiation, atypia and lack of proper keratiniza-
tion express less ASC (Fig 1B).
Interestingly, BCC as the most frequent malignant skin tumor with very rare metastasic
potential, lost expression of the tumor-suppressor / inflammasome adapter in all 5 cases ana-
lyzed (Fig 1C). In BCC, the tumor cells resemble basal keratinocytes as they arise from the low-
est layers of the epidermis or from the outer root sheath of the hair follicle. Keratinization is
therefore only rarely present. In contrast, condyloma acuminatum, an HPV-induced benign
epidermal hyperplasia arising mainly in the anogenital area did not lose ASC expression in all
5 cases stained (Fig 1D). Condylomata histologically display acanthotic thickening of the epi-
dermis representing benign epithelial tumors in opposition to malignant tumors such as SCC
or BCC.
Fig 1. The expression of ASC is reduced de-differentiated (G3) SCC and basal cell carcinoma (BCC), but not in benign HPV-induced
condyloma. a) Normal human epidermis and well differentiated SCC express ASC immunohistochemically and as shown in the insert ASC
expression is retained in areas of keratinization. while b) ASC expression is lost in de-differentiated G3 tumors, in particular in areas of poor
differentiation (insert) and in c) BCC, but not in d) HPV-induced benign condylomata acuminata.
doi:10.1371/journal.pone.0164742.g001
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While increasing vertical tumor thickness is reported to be associated with poorer prognosis
[3], ASC immunoreactivity did not correlate with tumor thickness (Fig 2A) or with its meta-
static potential (Table 1).
ASC is silenced in SCC cell lines via promotor-specific methylation
ASC is frequently silenced in malignant epithelial tumors such as BCC and SCC, but is con-
served in benign proliferations such as condylomata acuminata.We therefore screened various
SCC cancer cell lines and primary human keratinocytes for the expression of ASC. After RNA
isolation and cDNA synthesis, the cDNA is subjected to real-time PCR. Compared to primary
human keratinocytes, five of eight (62.5%) cutaneous and oral SCC-lines significantly lost ASC
expression (Fig 2C).
To elucidate the mechanism of how ASC is silenced, a methylation-specific PCR for ASC
was established. DNA was isolated from SCC022 which expresses similar amounts of ASC
compared to primary keratinocytes, and SCC028 in which ASC is almost entirely absent. Then,
Fig 2. ASC expression does not correlate with tumor thickness, but with the degree of dedifferentiation. Primary cutaneous squamous cell
carcinoma (SCC) samples were grouped according to a) tumor thickness and b) grade of differentiation, and ASC staining intensity was evaluated. c)
Human primary keratinocytes and various cutaneous or mucosal SCC cell lines were screened for ASC expression by real-time PCR. Primary
keratinocytes and 3 cell lines retain ASC expression, while 5 of 8 cell lines display reduced amounts of ASC cDNA.
doi:10.1371/journal.pone.0164742.g002
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DNA was incubated with bisulfite. Bisulfite converts cytosine to uracil, whereas methylated
5-methylcytosine does not react to bisulfite treatment. Therefore, specific primers exclusively
amplifying the unmethylated or methylated form of ASC were used. The commercially avail-
able fully methylated DNA only amplified using the methylated primer set, while normal DNA
only generated a band with the unmethylated ASC-primer pair. A PCR product for ASC in
SCC022 (which expresses ASC cDNA) could only be visualized using the unmethylated, but
not the methylated primers. As expected, SCC028, which does not express ASC in RT-PCR
only amplifies a product with the methylated primer set (Fig 3A). In conclusion, ASC-expres-
sion is silenced in SCC via promotor specificmethylation.
Fig 3. ASC is silenced in squamous cell carcinoma (SCC) cell lines by promotor specific methylation and demethylation restores
inflammasome function. a) Bisulfite treated DNA of SCC022 (high expression of ASC) and SCC028 was subjected to methylation specific PCR. In
SCC028 only primers detecting the methylated DNA generate a PCR product, indicating that ASC is lost by promotor specific methylation. b) In
SCC028 ASC protein expression can be restored by treatment with the demethylating agent 5-aza-2‘-deoxy-cytidine. c) Upon activation with the
NLRP3-activator UVB, only SCC022, but not SCC028 cells can cleave caspase-1. SCC028 cells being treated with 5-aza-2‘-deoxy-cytidine restore
their capability of inflammasome activation both for c) UVB. Upon treatment with 5-aza-2‘-deoxy-cytidine and d) transfection of dsDNA as activator of
the AIM2-inflammasome cells significantly secrete more IL-1α as sign of inflammasome activation (p = 0.0005).
doi:10.1371/journal.pone.0164742.g003
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Methylated ASC impairs and reversal of methylation restores
inflammasome activation in human SCC
5-azacytidine and 5-aza-2’-deoxycytidine are hypomethylating agents which are clinically used
in the treatment of myelodysplastic syndrome (MDS). MDS is a precursor of acute myeloid
leukemia and is characterized by several aberrantly methylated genes [13]. 5-azacytidine and
5-aza-2’-deoxycytidine are chemical analogues of cytosine. As cytosine is methylated to uracil,
azacytidine can substitute for cytosine and can cause hypomethylation and eventually induce
de-methylation. ASC expression is diminished by methylation in human SCC and SCC cell
lines and methylated ASCmight lead to reduced inflammasome activation. It was our aim to
determine whether demethylating agents could also restore inflammasome activation. There-
fore SCC022 and SCC028 cells were subjected to demethylating 5-aza-2‘-deoxy-cytidine. As
expected 5-aza-2‘-deoxy-cytidine restored ASC expression in SCC028 cells (Fig 3B). The cells
were then exposed to UVB treatment to activate the NLRP3 inflammasome. Interestingly,
SCC028 cells without 5-aza-2‘-deoxy-cytidine treatment could not activate the inflammasome,
measured by the secretion of cleaved, activated caspase-1.SCC022 cells, on the other hand,
which carry higher endogenous levels of ASC secreted caspase-1 p10 in response to UVB radia-
tion. After demethylation, both SCC028 and SCC022 cells secreted cleaved caspase-1 (Fig 3C).
Further, upon AIM2-activation via transfection of poly (dA:dT), IL-1α is only secreted after
5-aza-2‘-deoxy-cytidineexposure (Fig 3D). IL-1α is secreted in an inflammasome dependent
manner from bothmyeloid cells and keratinocytes and can be used as a marker for inflamma-
some activation in human keratinocytes [14]. Therefore promoter demethylation which is ther-
apeutically used in myeloid leukemia, leads to inflammasome activation, possibly inducing
unsuspected pro-inflammatory responses.
Discussion
As we demonstrated, ASC can, depending on the tissue, have tumor-suppressive or tumor-pro-
motive capacities [10]. In the inflammatory infiltrate ASC impairs IL-1 secretion with IL-1
being a pro-inflammatory, pro-tumorigenic protein, while in the tumor cells ASC serves as a
tumor-suppressor. As loss of ASC due to promotor-methylation impairs prognosis in cholan-
giocarcinoma [15] or lung cancer [16], we aimed to assess whether ASC is differently expressed
in metastatic versus non-metastatic primary cutaneous SCC. Comparing SCC of the identical
vertical tumor thickness that have or have not metastasized over a follow-up period of at least 4
years, we were not able to detect any difference in staining pattern. In contast to cholangiocar-
cinoma or lung carcinoma, keratinocytes are known to carry functional inflammasomes [7]
[17] which activate caspase-1 to induce IL-1 secretion. Lung epithelial cells have not been
reported as inflammasome containing cells. Putatively, IL-1 production of cells carryingASC
in cutaneous SCCmight counteract the loss of the tumor-suppressor, leading to balanced pro-
liferation. Additionally, cutaneous SCCs do not metastasize as frequently as lung or gall bladder
carcinoma, therefore the ratio of non-metastatic to metastatic SCC is high.
As dedifferentiation is a further prognostic marker in SCC classification, ASC staining was
correlated to G1 or G3 cutaneous SCCs. G1 tumors resemble normal squamous epithelia while
G3 tumors do not resemble the original keratinocytes.Hallmarks of poor differentiation are a
high number of mitotic figures and the lack of keratin pearls as zones of keratinization. Inter-
estingly, ASC was retained in G1 tumors being able to form keratin, while it was lost more fre-
quently in dedifferentiatedG3 tumors. These dedifferentiated tumors often resemble
mesenchymal tumors or scar tissue and no longer carry ASC. As ASC alters proliferation by
regulation of p53 activation [10] and p53 regulates epithelial-mesenchymal transition (EMT)
[18], ASCmight regulate the EMT-like dedifferentiation of keratinocytes. Condylomata
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acuminata, benignHPV-induced proliferations, showed the identical expression of ASC as the
epidermis, while BCCs lost the tumor suppressor. BCCs very often silence p53-dependent
genes by methylation [19], although they hardly ever metastasize. They originally never show
any signs of keratinization as their cells of origin are located near in basal keratinocytes or the
hair follicle. After having demonstrated that ASC is silenced in SCC by promotor specific
methylation, we screened SCC cell lines for the expression of ASC. Here, some cell lines lost
ASC, while others show the identical levels compared to primary keratinocytes. This reflects
the clinical presentation, as some SCCs grow slowly, while others grow rapidly. In comparing a
cell line that has lost ASC to a cell line where ASC expression is not altered, we were able to
restore ASC expression by treatment with a demethylating agent, which is used in the treat-
ment of myeloid leukemia. As expected,ASC was demethylated and became detectable on
cDNA and protein levels. Interestingly, functional ASC was also restored after treatment. The
tumor cells that silencedASC were not able to secrete IL-1 or cleave caspase-1. However, after
ASC restoration by 5-aza-2‘-deoxy-cytidine the cells responded upon inflammasome activation
with caspase-1 cleavage and IL-1 secretion. Therefore, we could for the first time demonstrate
that promotor methylation influences inflammasome activation. This could be of therapeutic
relevance, as some treatment options for early epithelial skin cancer demand immune activa-
tion. Imiquimod, which is used for superficial SCC and BCC and genital warts, is a ligand for
both TLR7 and NLRP3, therefore inducing both IL-1 and interferon. Futhermore, the anti-can-
cer effect of ingenol mebutate which is used for the treatment of cutaneous SCC in situ is medi-
ated via IL-1 [20].
In conclusion, ASC expression cannot be exploited as a prognostic marker for metastasis,
but serves as an indicator for highly differentiated tumors. The dual capacity of ASC being an
inflammasome adaptor regulating caspase-1 and IL-1 activation, but also controlling prolifera-
tion is restored in cutaneous SCC. The tumor cells can only activate pro-tumorigenic IL-1 if
the tumor suppressor ASC is expressed. Therefore, further studies are needed to enhance the
understanding of inflammasome regulation in tumor cells via methylation and de-methylation
of target genes.
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